Genethon: green light from the ANSM to start a gene therapy trial for Duchenne.D

Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorisation from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004. This trial’s…

Increasing HPV vaccine uptake in adolescents

PHILADELPHIA (December 1, 2020) – More than 90 percent of human papillomavirus (HPV)-related cancers could be prevented by widespread uptake of the HPV vaccine. Yet, vaccine use in the United States falls short of public health goals. In an article in JMIR Nursing, researchers explain how they applied user-centered design principles to develop a mobile…

COVID-19 may deepen depression, anxiety, and PTSD among pregnant and postpartum women

Boston — Though childbirth is often anticipated with optimism and enthusiasm, approximately 10 to 20 percent of pregnant individuals also experience mental health challenges during the weeks immediately before and after birth. Depression, anxiety and trauma-related disorders can all be exacerbated by increased stress related to pregnancy and postpartum experiences. But it’s unknown how the…

OHDSI awarded $10 MM FDA contract to monitor safety/effectiveness of vaccines, biologics

NEW YORK, NY (Dec. 1, 2020)–Researchers within the Observational Health Data Services and Informatics (OHDSI) community were recently awarded a $10 million contract from the U.S. Food and Drug Administration (FDA) to provide support to the Biologics Effectiveness and Safety (BEST) program, which was launched by the FDA Center for Biologics Evaluation and Research (CBER)…